Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma
Cellular Biomedicine Group announced early data from its ongoing investigator initiated trial (at an oral presentation titled "Novel Anti-BCMA CAR-T for Relapsed or Refractory Multiple Myeloma" at the American Society of Hematology annual meeting. A Phase 1, dose escalation trial is being conducted in patients with relapsed or refractory multiple myeloma to assess the safety and efficacy of C-CAR088. As of the end of November the company has enrolled eleven patients, of which eight were infused with C-CAR088, and five patients were evaluable for clinical response. Three of the five patients were treated with C-CAR088 at the dose of 1.0 x 106 CAR-T cells/kg, and the other two patients treated at 3.0x106 CAR-T cells/kg. All five patients showed clinical improvement as early as two weeks post treatment, Cellular Biomedicine said in a statement. By four weeks, one patient achieved a complete response, three patients reached a very good partial response, and one patient reached a partial response post C-CAR088 infusion, the company said. Furthermore, Cellular Biomedicine observed that C-CAR088 proliferation and expansion in the peripheral blood correlated with the decrease of tumor burden in all patients. C-CAR088 treatment showed to be well tolerated, it added.